


PHARMACEUTICAL 2020

ABBOTT LABORATORIES Rank 22 of 362









RealRate

PHARMACEUTICAL 2020



ABBOTT LABORATORIES Rank 22 of 362

The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 372% points. The greatest weakness of ABBOTT LABORATORIES is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 496% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	15,667,000
Cost of Goods Sold	13,231,000
Intangible Assets	40,220,000
Liabilities, Current	10,863,000
Liabilities, Non-Current	0
Other Assets	3,962,000
Other Compr. Net Income	-879,000
Other Expenses	2,996,000
Other Liabilities	0
Other Net Income	215,000
Property and Equipment	8,038,000
Research and Development	2,440,000
Revenues	31,904,000
Selling, General and Administrative Expense	9,765,000

Output Variable	Value in 1000 USD
Assets	67,887,000
Liabilities	10,863,000
Expenses	28,432,000
Stockholders Equity	57,024,000
Net Income	3,687,000
Comprehensive Net Income	3,247,500
Economic Capital Ratio	193%

